If MNTA were to ink a comprehensive FoB deal with PFE, do you see any chance of MNTA being able to carve out rights to partner a substitutable Enbrel FoB with another party?
No, I don’t see any chance of that.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”